DOCSLIB.ORG

Illinois Register Department of Public Health Notice Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Illinois Register Department of Public Health Notice Of ILLINOIS REGISTER DEPARTMENT OF PUBLIC HEALTH NOTICE OF EMERGENCY AMENDMENT TITLE 77: PUBLIC HEALTH CHAPTER I: DEPARTMENT OF PUBLIC HEALTH SUBCHAPTER k: COMMUNICABLE DISEASE CONTROL AND IMMUNIZATIONS PART 690 CONTROL OF COMMUNICABLE DISEASES CODE SUBPART A: GENERAL PROVISIONS Section 690.10 Definitions 690.20 Incorporated and Referenced Materials 690.30 General Procedures for the Control of Communicable Diseases 690.50 Pandemic or Epidemic Respiratory Disease – Emergency Provisions EMERGENCY SUBPART B: REPORTABLE DISEASES AND CONDITIONS Section 690.100 Diseases and Conditions 690.110 Diseases Repealed from This Part SUBPART C: REPORTING Section 690.200 Reporting SUBPART D: DETAILED PROCEDURES FOR THE CONTROL OF COMMUNICABLE DISEASES Section 690.290 Acquired Immunodeficiency Syndrome (AIDS) (Repealed) 690.295 Any Unusual Case of a Disease or Condition Caused by an Infectious Agent Not Listed in this Part that is of Urgent Public Health Significance (Reportable by telephone immediately (within three hours)) 690.300 Amebiasis (Reportable by mail, telephone, facsimile or electronically as soon as possible, within 7 days) (Repealed) 690.310 Animal Bites (Reportable by mail or telephone as soon as possible, within 7 days) (Repealed) 690.320 Anthrax (Reportable by telephone immediately, within three hours, upon initial clinical suspicion of the disease) ILLINOIS REGISTER DEPARTMENT OF PUBLIC HEALTH NOTICE OF EMERGENCY AMENDMENT 690.322 Arboviral Infections (Including, but Not Limited to, Chikungunya Fever, California Encephalitis, St. Louis Encephalitis, Dengue Fever and West Nile Virus) (Reportable by mail, telephone, facsimile or electronically as soon as possible, within seven days) 690.325 Blastomycosis (Reportable by telephone as soon as possible, within 7 days) (Repealed) 690.327 Botulism, Foodborne, Intestinal Botulism (Formerly Infant), Wound, or Other (Reportable by telephone immediately, within three hours upon initial clinical suspicion of the disease for foodborne botulism or within 24 hours by telephone or facsimile for other types) 690.330 Brucellosis (Reportable by telephone as soon as possible (within 24 hours), unless suspect bioterrorist event or part of an outbreak, then reportable immediately (within three hours) by telephone) 690.335 Campylobacteriosis (Reportable by mail, telephone, facsimile or electronically, within 7 days) 690.340 Chancroid (Repealed) 690.350 Chickenpox (Varicella) (Reportable by telephone, facsimile or electronically , within 24 hours) 690.360 Cholera (Toxigenic Vibrio cholerae O1 or O139) (Reportable by telephone or facsimile as soon as possible, within 24 hours) 690.362 Creutzfeldt-Jakob Disease (CJD) (All Laboratory Confirmed Cases) (Reportable by mail, telephone, facsimile or electronically within Seven days after confirmation of the disease) (Repealed) 690.365 Cryptosporidiosis (Reportable by mail, telephone, facsimile or electronically as soon as possible, within seven days) 690.368 Cyclosporiasis (Reportable by mail, telephone, facsimile or electronically, within seven days) 690.370 Diarrhea of the Newborn (Reportable by telephone as soon as possible, within 24 hours) (Repealed) 690.380 Diphtheria (Reportable by telephone immediately, within three hours, upon initial clinical suspicion or laboratory test order) 690.385 Ehrlichiosis, Human Granulocytotropic anaplasmosis (HGA) (See Tickborne Disease) 690.386 Ehrlichiosis, Human Monocytotropic (HME) (See Tickborne Disease) 690.390 Encephalitis (Reportable by mail, telephone, facsimile or electronically as soon as possible, within 7 days) (Repealed) 690.400 Escherichia coli Infections (E. coli O157:H7 and Other Shiga Toxin Producing E. coli) (Reportable by telephone or facsimile as soon as possible, within 24 hours) 690.410 Foodborne or Waterborne Illness (Reportable by telephone or facsimile as soon as possible, within 24 hours) (Repealed) ILLINOIS REGISTER DEPARTMENT OF PUBLIC HEALTH NOTICE OF EMERGENCY AMENDMENT 690.420 Giardiasis (Reportable by mail, telephone, facsimile or electronically as soon as possible, within 7 days) (Repealed) 690.430 Gonorrhea (Repealed) 690.440 Granuloma Inguinale (Repealed) 690.441 Haemophilus Influenzae, Meningitis and Other Invasive Disease (Reportable by telephone or facsimile, within 24 hours) 690.442 Hantavirus Pulmonary Syndrome (Reportable by telephone as soon as possible, within 24 hours) 690.444 Hemolytic Uremic Syndrome, Post-diarrheal (Reportable by telephone or facsimile, within 24 hours) 690.450 Hepatitis A (Reportable by telephone or facsimile as soon as possible, within 24 hours) 690.451 Hepatitis B and Hepatitis D (Reportable by mail, telephone, facsimile or electronically, within seven days) 690.452 Hepatitis C, Acute Infection and Non-acute Confirmed Infection (Reportable by mail, telephone, facsimile or electronically, within seven days) 690.453 Hepatitis, Viral, Other (Reportable by mail, telephone, facsimile or electronically, within 7 days) (Repealed) 690.460 Histoplasmosis (Reportable by mail, telephone, facsimile or electronically as soon as possible, within seven days) 690.465 Influenza, Death (in persons less than 18 years of age) (Reportable by mail, telephone, facsimile or electronically as soon as possible, within 7 days) 690.468 Influenza (Laboratory Confirmed (Including Rapid Diagnostic Testing)) Intensive Care Unit Admissions (Reportable by telephone or facsimile or electronically as soon as possible, within 24 hours) 690.469 Influenza A, Variant Virus (Reportable by telephone immediately, within three hours upon initial clinical suspicion or laboratory test order) 690.470 Intestinal Worms (Reportable by mail or telephone as soon as possible, within 7 days) (Repealed) 690.475 Legionellosis (Reportable by mail, telephone, facsimile or electronically as soon as possible, within seven days) 690.480 Leprosy (Hansen's Disease) (Infectious and Non-infectious Cases are Reportable) (Reportable by mail, telephone, facsimile or electronically as soon as possible, within seven days) (Repealed) 690.490 Leptospirosis (Reportable by mail, telephone, facsimile or electronically as soon as possible, within seven days) 690.495 Listeriosis (When Both Mother and Newborn are Positive, Report Mother Only) (Reportable by mail, telephone, facsimile or electronically as soon as possible, within seven days) 690.500 Lymphogranuloma Venereum (Lymphogranuloma Inguinale Lymphopathia ILLINOIS REGISTER DEPARTMENT OF PUBLIC HEALTH NOTICE OF EMERGENCY AMENDMENT Venereum) (Repealed) 690.505 Lyme Disease (See Tickborne Disease) 690.510 Malaria (Reportable by mail, telephone, facsimile or electronically as soon as possible, within seven days) 690.520 Measles (Reportable by telephone as soon as possible, within 24 hours) 690.530 Meningitis, Aseptic (Including Arboviral Infections) (Reportable by mail, telephone, facsimile or electronically as soon as possible, within 7 days) (Repealed) 690.540 Meningococcemia (Reportable by telephone as soon as possible) (Repealed) 690.550 Mumps (Reportable by telephone, facsimile or electronically as soon as possible, within 24 hours) 690.555 Neisseria meningitidis, Meningitis and Invasive Disease (Reportable by telephone or facsimile as soon as possible, within 24 hours) 690.560 Ophthalmia Neonatorum (Gonococcal) (Reportable by mail or telephone as soon as possible, within 7 days) (Repealed) 690.565 Outbreaks of Public Health Significance (Including, but Not Limited to, Foodborne or Waterborne Outbreaks) (Reportable by telephone or electronically as soon as possible, within 24 hours) 690.570 Plague (Reportable by telephone immediately, within three hours upon initial clinical suspicion of the disease) 690.580 Poliomyelitis (Reportable by telephone immediately, within three hours) upon initial clinical suspicion of the disease) 690.590 Psittacosis (Ornithosis) Due to Chlamydia psittaci (Reportable by mail, telephone, facsimile or electronically as soon as possible, within seven days) 690.595 Q-fever Due to Coxiella burnetii (Reportable by telephone as soon as possible, within 24 Hours, unless suspect bioterrorist event or part of an outbreak, then reportable immediately (within three hours) by telephone) 690.600 Rabies, Human (Reportable by telephone or facsimile as soon as possible, within 24 hours) 690.601 Rabies, Potential Human Exposure and Animal Rabies (Reportable by telephone or facsimile, within 24 hours) 690.610 Rocky Mountain Spotted Fever (See Tickborne Disease) 690.620 Rubella (German Measles) (Including Congenital Rubella Syndrome) (Reportable by telephone, facsimile or electronically as soon as possible, within 24 hours) 690.630 Salmonellosis (Other than Typhoid Fever) (Reportable by mail, telephone, facsimile or electronically as soon as possible, within seven days) 690.635 Severe Acute Respiratory Syndrome (SARS) (Reportable by telephone immediately (within 3 hours) upon initial clinical suspicion of the disease) 690.640 Shigellosis (Reportable by mail, telephone, facsimile or electronically as soon as possible, within seven days) ILLINOIS REGISTER DEPARTMENT OF PUBLIC HEALTH NOTICE OF EMERGENCY AMENDMENT 690.650 Smallpox (Reportable by telephone immediately, within three hours upon initial clinical suspicion of the disease) 690.655 Smallpox vaccination, complications of (Reportable by telephone or electronically as soon as possible, within 24 hours) 690.658 Staphylococcus aureus, Methicillin Resistant (MRSA) Infection, Clusters of Two or More Laboratory Confirmed Cases Occurring in Community Settings (Including, but Not Limited to, Schools, Correctional
Load more

Recommended publications
  • Reportable Disease Surveillance in Virginia, 2013
    Reportable Disease Surveillance in Virginia, 2013 Marissa J. Levine, MD, MPH State Health Commissioner Report Production Team: Division of Surveillance and Investigation, Division of Disease Prevention, Division of Environmental Epidemiology, and Division of Immunization Virginia Department of Health Post Office Box 2448 Richmond, Virginia 23218 www.vdh.virginia.gov ACKNOWLEDGEMENT In addition to the employees of the work units listed below, the Office of Epidemiology would like to acknowledge the contributions of all those engaged in disease surveillance and control activities across the state throughout the year. We appreciate the commitment to public health of all epidemiology staff in local and district health departments and the Regional and Central Offices, as well as the conscientious work of nurses, environmental health specialists, infection preventionists, physicians, laboratory staff, and administrators. These persons report or manage disease surveillance data on an ongoing basis and diligently strive to control morbidity in Virginia. This report would not be possible without the efforts of all those who collect and follow up on morbidity reports. Divisions in the Virginia Department of Health Office of Epidemiology Disease Prevention Telephone: 804-864-7964 Environmental Epidemiology Telephone: 804-864-8182 Immunization Telephone: 804-864-8055 Surveillance and Investigation Telephone: 804-864-8141 TABLE OF CONTENTS INTRODUCTION Introduction ......................................................................................................................................1
    [Show full text]
  • Sexually Transmitted Infections Introduction and General Considerations Date Reviewed: July, 2010 Section: 5-10 Page 1 of 13
    Sexually Transmitted Infections Introduction and General Considerations Date Reviewed: July, 2010 Section: 5-10 Page 1 of 13 Background Information The incidence of Sexually Transmitted Infections (STIs) in Saskatchewan has been increasing over the past number of years. This may be due in part to the introduction of testing procedures that are easier to complete and less invasive. In Saskatchewan, the rates for chlamydia have been among the highest in Canada. Refer to http://dsol- smed.phac-aspc.gc.ca/dsol-smed/ndis/c_indp_e.html#c_prov for historical surveillance data collected by Public Health Agency of Canada (PHAC). STIs are transmitted in the context of other social and health challenges; the risk of recurrent exposure and infection are likely unless these underlying issues are dealt with. A holistic assessment of clients assists in identifying these underlying issues and a multidisciplinary team approach is often necessary and should involve other partners such as physicians, addiction services and mental health as required. The regulations of The Health Information Protection Act must be adhered to when involving other partners in the management of individuals or when referring individuals to other agencies. This section highlights some of the general and special considerations that should be kept in mind when conducting STI investigations. It also highlights key points and summarizes the Canadian Guidelines on Sexually Transmitted Infections which can be located at http://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php. Reporting Requirements Index cases must be reported to the Ministry of Health. See Reporting Requirements in the General Information section of this manual for additional information and guidelines.
    [Show full text]
  • Lymphogranuloma Venereum (LGV) Reporting and Case Investigation
    Public Health and Primary Health Care Communicable Disease Control 4th Floor, 300 Carlton St, Winnipeg, MB R3B 3M9 T 204 788-6737 F 204 948-2040 www.manitoba.ca November, 2015 Re: Lymphogranuloma Venereum (LGV) Reporting and Case Investigation Reporting of LGV (Chlamydia trachomatis L1, L2 and L3 serovars) is as follows: Laboratory: All positive laboratory results for Chlamydia trachomatis L1, L2 and L3 serovars are reportable to the Public Health Surveillance Unit by secure fax (204-948- 3044). Health Care Professional: For Public Health investigation and to meet the requirement for contact notification under the Reporting of Diseases and Conditions Regulation in the Public Health Act, the Notification of Sexually Transmitted Disease (NSTD) form ( http://www.gov.mb.ca/health/publichealth/cdc/protocol/form3.pdf ) must be completed for all laboratory-confirmed cases of LGV. Please check with the public health office in your region with respect to procedures for return of NSTD forms for case and contact investigation. Cooperation with Public Health investigation is appreciated. Regional Public Health or First Nations Inuit Health Branch: Return completed NSTD forms to the Public Health Surveillance Unit by mail (address on form) or secure fax (204-948-3044). Sincerely, “Original Signed By” “Original Signed By” Richard Baydack, PhD Carla Ens, PhD Director, Communicable Disease Control Director, Epidemiology & Surveillance Public Health and Primary Health Care Public Health and Primary Health Care Manitoba Health, Healthy Living and Seniors Manitoba Health, Healthy Living and Seniors Communicable Disease Management Protocol Lymphogranuloma Venereum (LGV) Communicable Disease Control Unit Etiology distinct stages (2, 9). Primary infection appears three to 30 days after infection (2, 8) and presents LGV is caused by Chlamydia trachomatis (C.
    [Show full text]
  • Laboratory Diagnosis of Sexually Transmitted Infections, Including Human Immunodeficiency Virus
    Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus human immunodeficiency including Laboratory transmitted infections, diagnosis of sexually Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus Editor-in-Chief Magnus Unemo Editors Ronald Ballard, Catherine Ison, David Lewis, Francis Ndowa, Rosanna Peeling For more information, please contact: Department of Reproductive Health and Research World Health Organization Avenue Appia 20, CH-1211 Geneva 27, Switzerland ISBN 978 92 4 150584 0 Fax: +41 22 791 4171 E-mail: [email protected] www.who.int/reproductivehealth 7892419 505840 WHO_STI-HIV_lab_manual_cover_final_spread_revised.indd 1 02/07/2013 14:45 Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus Editor-in-Chief Magnus Unemo Editors Ronald Ballard Catherine Ison David Lewis Francis Ndowa Rosanna Peeling WHO Library Cataloguing-in-Publication Data Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus / edited by Magnus Unemo … [et al]. 1.Sexually transmitted diseases – diagnosis. 2.HIV infections – diagnosis. 3.Diagnostic techniques and procedures. 4.Laboratories. I.Unemo, Magnus. II.Ballard, Ronald. III.Ison, Catherine. IV.Lewis, David. V.Ndowa, Francis. VI.Peeling, Rosanna. VII.World Health Organization. ISBN 978 92 4 150584 0 (NLM classification: WC 503.1) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html).
    [Show full text]
  • The Returning Traveller with Fever
    PG133-138 3/10/05 4:35 PM Page 133 THE TRAVELLER WITH FEVER THE RETURNING TRAVELLER WITH FEVER As numbers of visitors returning from exotic destinations in less developed parts of the world increase, the challenges to the physician grow. Travellers face a number of health risks during their journeys. The majority of incidents are related to trauma or to underly- ing co-morbid disease, most commonly cardiovascular dis- ease. Infectious diseases however are a significant problem and range from the potentially life-threatening, such as malaria, to those that are more mundane, such as travellers’ diarrhoea. This article will focus on the traveller who returns with a suspected infectious disease and will discuss a diag- nostic approach, before describing important syndromes and their common causes. HISTORY LUCILLE BLUMBERG JOHN FREAN Pyrexial illness is a presentation of most travel-associated MB BCh, MMed (Microbiol), MB BCh, MMed (Path), infectious diseases, but many common infections such as DTM&H, DOH, DCH DTM&H, MSc (Med Parasitol) influenza and pneumonia also occur in the tropics or may be Specialist Microbiologist Specialist Microbiologist acquired en route to and from exotic regions. Patients may National Institute for National Institute for also have chronic or recurrent medical problems that are Communicable Diseases and Communicable Diseases and unrelated to their tropical exposure. In approaching a pyrexi- University of the University of the al patient, therefore, a general medical history should elicit Witwatersrand Witwatersrand Johannesburg Johannesburg the presence of underlying conditions, particularly those John Frean qualified at the associated with increased risk of infections such as diabetes, Lucille Blumberg is currently University of the malignancy, HIV infection, splenectomy, and pregnancy.
    [Show full text]
  • August 2017 Preliminary
    Mecklenburg County Health Department Reportable Communicable Diseases Reported to NC Department of Health and Human Services Monthly Report: AUGUST 2017 Reflects report dates, not always onset dates Preliminary Figures HIV/AIDS & Syphilis case reports are currently unavailable due to changes in reporting system (Year to Date) DISEASES January February March April May June July August September October November December 2017 Total Cases AUG 3 year Average Year-to-Date(3 Year Average) AIDS** 1,3 - - - - - - - - - - - Chancroid** 0 0 0 0 0 0 0 0 0 0 0 Chlamydia (Laboratory confirmed)3 703 777 884 671 855 905 853 758 6406 452 4651 Gonorrhea**3 259 240 305 245 308 328 280 321 2286 153 1538 Granuloma Inguinale** 0 0 0 0 0 0 0 0 0 0 0 Hep. Type B, Acute** 0 0 0 0 2 0 0 3 5 1 5 Hep. Type B, Carrier 4 5 0 11 10 3 0 26 59 12 90 Perinatal Hepatitis B** 0 0 0 0 0 0 0 0 0 0 0 Hep. Type C, Acute 0 1 0 0 0 0 0 0 1 0 3 HIV Disease**1,3 - - - - - - - - - - - Lymphogranuloma Venereum 0 0 0 0 0 0 0 0 0 0 0 Nongonococcal Urethritis (NGU) 18 17 55 46 7 30 50 42 265 15 117 Ophthalmia Neonatorum 0 0 0 0 0 0 0 0 0 0 0 Sexually and Bloodborne Transmittted Pelvic Inflammatory Disease (PID) 0 0 0 7 0 2 3 4 16 0 0 Syphilis**1,3 - - - - - - - - - - - Congenital Syphilis**3 - - - - - - - - - - - Botulism2 0 0 0 0 0 0 0 0 0 0 0 Campylobacter Infection** 3 1 2 4 8 2 10 6 36 7 45 Cholera** 0 0 0 0 0 0 0 0 0 0 0 Cryptosporidiosis** 2 1 0 0 0 0 2 4 9 2 12 Cyclosporiasis** 0 0 0 0 0 1 1 2 4 0 0 C.
    [Show full text]
  • NYS DOH STD Reporting Form
    To order more copies of this form call the Provider Access Line: 1-866-NYC-DOH1 NYC Department of Health & Mental Hygiene Universal Reporting Form PHA No. Form PD-16 (9/09) Mail completed form to: NYC Dept. of Health & Mental Hygiene; 125 Worth Street, Room 315, CN-6; New York, NY 10013 • Or report online: www.nyc.gov/nycmed P Patient Last Name First Name Middle Name DATE OF REPORT A T Patient AKA: Last Name AKA: First Name M.I . I ____ / ____ / ____ E Date of Birth Age Country of Birth Soc.Sec.No. N T ____ / ____ / ________ If patient is a child, Guardian Last Name Guardian First Name M.I. Ⅺ Homeless I Borough: Manhattan N Patient Home Address Apt. No. Zip Code Bronx F Unknown Brooklyn O Home Telephone Number Medical Record Number ( _______ ) ________ – _____________ Queens R Unknown M Staten Island Other Telephone Number Medicaid Number Ⅺ NYC, borough unknown A Unknown ( _______ ) ________ – _____________ Unknown T Ⅺ I Sex Race (Check all that apply) Ethnicity Hispanic Please report non-NYC Not NYC (Specify City/State) Male Transexual Asian White American Indian/Alaska Native Unknown (Check one) Non-Hispanic residents to the appropriate ________________, _____ O N Female Unknown Black Other race Native Hawaiian/Pacific Islander Unknown health jurisdiction Ⅺ Unknown Admitted to hospital? Admission Date Is patient alive? If no, date of death Unknown Is patient pregnant? If yes, due date Yes No ____ / ____ / ________ Unknown Yes No Yes No Unknown Discharge Date Unknown ____ / ____ / ________ Unknown Unknown
    [Show full text]
  • Part 1: NC Confidential Communicable Disease Report NC EDSS Instructions for Completing
    Part 1: NC Confidential Communicable Disease Report NC EDSS Instructions for Completing This form is used by physicians to make a written report of a communicable disease to the local health department. 1. Enter NC Disease Code number for the disease being reported. (Refer to list of NC Disease Code numbers on page 2 of Part 1) 2. Provide Demographic Information for the Patient Name…last name, first Birthdate…(dd/mm/yyyy) Sex Parent or Guardian, if patient is a minor Patient Identifier May enter medical chart number or identifier - optional Social Security Number (SSN) Enter only if number is known to be accurate. Address, City, State, Zip Code …where patient is currently living County…patient’s current county of residence Phone…number where patient can be reached Age Enter age in months if patient is less than 12 months. Enter age in years only if patient is 12 months or older. Race and Ethnic Origin - Complete both sections. Was patient hospitalized for this disease? (>24 hours) Enter “Yes” only if hospitalization occurred as a result of the reported disease. Did patient die from this disease? Enter “Yes” only if the reported disease was the primary cause of death. Is the patient pregnant? Enter “Yes” only if the patient is currently pregnant. Patient is associated with… This information is especially important for respiratory and enteric diseases. In what geographic location was the patient MOST LIKELY exposed? Indicate where the disease was acquired. 3. Clinical Findings Is/was patient symptomatic for this disease? Enter “Yes” if symptoms of reported disease are/were present Symptom onset date (dd/mm/yyyy)…date symptoms began Specify symptoms List symptoms experienced as a result of reported disease NC Communicable Disease Manual/NC EDSS/ Instructions for NC EDSS Surveillance Forms Part 1: NC Confidential Communicable Disease Report July 2009 Page 1 of 2 Treatment details For Sexually Transmitted Diseases, provide specifics of treatment, administration date, medication, dose, duration of treatment.
    [Show full text]
  • Descriptive Epidemiology of Reportable Diseases
    DESCRIPTIVE EPIDEMIOLOGY OF REPORTABLE DISEASES ________________________________________________2004 Acquired Immunodeficiency Syndrome (AIDS) See Human Immunodeficiency Virus (HIV) Amebiasis Amebiasis is a parasitic infection transmitted by food or water contaminated by fecal matter containing Entameoba histolytica. Infection with amebic cysts can be asymptomatic. When infection causes disease, symptoms may include severe diarrhea, chills, or mild to moderate abdominal cramps, coupled with periods of remission. Occasionally, bloody diarrhea and fever may occur. Invasive amebiasis is most often found in young adults and is very rare in children under two years of age. There were 25 cases of amebiasis reported in Virginia in 2004. Although this is a 5% decrease from the five year average of 26.2 cases per year, it marks the third year in a row of increasing numbers of cases (Figure 1). Figure 1. Amebiasis: Ten Year Trend, Virginia, 1995-2004 40 35 30 25 20 15 10 Number of Cases 5 0 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Year 5 Year Average Reference Level (1999-2003) Twenty-three cases (92%) were reported in persons 20 years or older. The 30-39 year age group had the highest incidence rate with 0.6 per 100,000. No cases occurred in infants. Forty percent of cases had no race reported. Among cases with a reported race, the black population had the highest infection rate (0.5 per 100,000). Most cases (16) occurred in the northern region, which had an incidence rate of 0.8 per 100,000. This was followed by the northwest region (5 cases, 0.4 per 100,000).
    [Show full text]
  • Notifiable Conditions & the Health Care Provider
    Notifiable Conditions & the Health Care Provider The following conditions are notifiable to Public Health – Seattle & King County in accordance with WAC 246-101. Timeframes for notification are footnoted. Immediately notifiable conditions in bold should be reported when suspected or confirmed. Acquired immunodeficiency syndrome (AIDS) (including Lymphogranuloma venereum 3d AIDS in persons previously reported with HIV infection) 3d Malaria 3d Animal bites (when human exposure to rabies is suspected) Imm Measles (rubeola) acute disease only Imm Anthrax Imm Meningococcal disease (invasive) Imm Arboviral disease (West Nile virus disease, dengue, Eastern & Monkeypox Imm 3d Western equine encephalitis, St Louis encephalitis, and Powassan) Mumps (acute disease only) 24h Botulism (foodborne, wound and infant) Imm Outbreaks of suspected foodborne origin Imm Brucellosis (Brucella species) 24h Outbreaks of suspected waterborne origin Imm Imm Burkholdier mallei (Glanders) and pseudomallei (Melioidosis) Paralytic shellfish poisoning Imm 3d Campylobacteriosis Pertussis 24h 3d Chancroid Plague Imm 3d Chlamydia trachomatis infection Poliomyelitis Imm Cholera Imm Prion disease 3d Imm Coronavirus (MERS-CoV, SARS, Other Novel Coronavirus) Psittacosis 24h 3d Cryptosporidiosis Q fever 24h Cyclosporiasis 3d Rabies (confirmed human or animal) Imm Diphtheria Imm Rabies, suspected human exposure Imm Imm Disease of suspected bioterrorism origin Relapsing fever (borreliosis) 24h Domoic acid poisoning Imm Rubella (including congenital rubella syndrome) Imm E. coli
    [Show full text]
  • That Other Chlamydia: Lymphogranulom a Venereum (LGV)
    Clinical Education Initiative [email protected] That Other Chlamydia: Lymphogranulom a Venereum (LGV) Speaker: Marguerite Urban, MD 4/4/2018 That Other Chlamydia: Lymphogranuloma Venereum (LGV) [video transcript] [00:00:06] All right. So, today I'm going to talk about the other Chlamydia known as Lympogranuloma Venerium, which we often abbreviate LGV. Just the objectives, are to go over the clinical manifestations of LGV and review the current treatment recommendations. I have no financial disclosures, but I will talk about some non FDA approved diagnostic testing that is described in the literature. So, first just a little bit of background, I'm sure you're all familiar with Chlamydia Trachomatis, but LGV is caused really by a different different serovars of that typical chlamydia that you think of. Conveniently, the L1 through L3 serovars are the ones that cause LGV. As a side note I don't think I've ever taken any sort of board test were there, that was not asked on the exam. So, it seems to be a favorite question for any of you who might be in training. Historically, LGV was most common in tropical and subtropical climates, Africa, Southeast, Asia, the Caribbean, and it's been known about for quite some time; it was first described as a distinct clinical entity way back in 1913. Since 2003, this formerly, relatively unusual Western pathogen has been described with increasing frequency in both Europe and North America. And these reports have largely been coming out of men who have sex with men communities, who also had high rates of HIV co-infection.
    [Show full text]
  • Aureomycin in the Treatment of Granuloma Inguinale And
    AUREOMYCIN IN THE TREATMENT OF GRANIJLOMA INGUINALE AND LYMPHOGRANULOMA VENEREUM* VIRGENE S. WAMMOCK, M.D., ROBERT B. GREENBLATT, M.D., ROBERT B. DIENST, PH.D., CALVIN CHEN, M.D. AND ROBERT M. WEST, B.S. Physicians have long searched for an effective therapeutic agent against the unusually resistant diseases, granuloma inguinale and lymphogranuloma yen- ereum. Chancroid responds readily to antiseptic measures and the sulfonamide compounds. Syphilis is controlled by penicillin or arsenicals and bismuth com- pounds. Gonorrhea responds to the sulfonamides, penicillin or streptomycin. The discovery that streptomycin was effective in the treatment of granuloma in- guinale at last offered new hope to the patient with advanced and resistant lesions. None of the antibiotics however, proved of any value in lymphogranu- loma venereum until aureomycin and chloromycetin became available. This re- port deals only with our experience in the management with aureomycin of 20 patients having granuloma inguinale and 20 with lymphogranuloma venereum. GRANULOMA INGUINALE Granuloma inguinale has been one of the recalcitrant diseases of the South. When treated early and when the lesions were relatively small they responded to prolonged therapy with the antimony compounds. However, relapses were common (1). Soon after streptomycin became available Greenhlatt, Kupperman and Dienet (2) found it offered great hope for the cure of granuloma inguinale. The average effective dose was found to be 20 grams of streptomycin in 5 days. When this dosage schedule was employed in 95 cases of 142 patients treated a cure rate of 90.4% was obtained. However, 5 streptomycin-resistant cases were encountered. These patients received from 40 to 158 grams without benefit.
    [Show full text]